Cargando…

Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure–Activity Relationship Insights and Evolution Perspectives

[Image: see text] The viral main protease is one of the most attractive targets among all key enzymes involved in the SARS-CoV-2 life cycle. Covalent inhibition of the cysteine(145) of SARS-CoV-2 M(PRO) with selective antiviral drugs will arrest the replication process of the virus without affecting...

Descripción completa

Detalles Bibliográficos
Autores principales:	La Monica, Gabriele, Bono, Alessia, Lauria, Antonino, Martorana, Annamaria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528073/ https://www.ncbi.nlm.nih.gov/pubmed/36169610 http://dx.doi.org/10.1021/acs.jmedchem.2c01005

Ejemplares similares

Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors
por: Monica, Gabriele La, et al.
Publicado: (2021)

In Silico Insights into the SARS CoV-2 Main Protease Suggest NADH Endogenous Defences in the Control of the Pandemic Coronavirus Infection
por: Martorana, Annamaria, et al.
Publicado: (2020)

In Silico Design of New Dual Inhibitors of SARS-CoV-2 M(PRO) through Ligand- and Structure-Based Methods
por: Bono, Alessia, et al.
Publicado: (2023)

In Silico Mixed Ligand/Structure-Based Design of New CDK-1/PARP-1 Dual Inhibitors as Anti-Breast Cancer Agents
por: Bono, Alessia, et al.
Publicado: (2023)

Quinoline-Based Molecules Targeting c-Met, EGF, and VEGF Receptors and the Proteins Involved in Related Carcinogenic Pathways
por: Martorana, Annamaria, et al.
Publicado: (2020)

Design and Synthesis of Novel Thieno[3,2-c]quinoline Compounds with Antiproliferative Activity on RET-Dependent Medullary Thyroid Cancer Cells
por: La Monica, Gabriele, et al.
Publicado: (2023)

Antiproliferative Activity Predictor: A New Reliable In Silico Tool for Drug Response Prediction against NCI60 Panel
por: Martorana, Annamaria, et al.
Publicado: (2022)

In Silico Identification of Small Molecules as New Cdc25 Inhibitors through the Correlation between Chemosensitivity and Protein Expression Pattern
por: Lauria, Antonino, et al.
Publicado: (2021)

Antiproliferative Properties and G-Quadruplex-Binding of Symmetrical Naphtho[1,2-b:8,7-b’]dithiophene Derivatives
por: Lauria, Antonino, et al.
Publicado: (2021)

Identification of and Mechanistic Insights into SARS-CoV-2 Main Protease Non-Covalent Inhibitors: An In-Silico Study
por: Shen, Jian-Xin, et al.
Publicado: (2023)

Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
por: Kneller, Daniel W., et al.
Publicado: (2022)

Repurposing Halicin as a potent covalent inhibitor for the SARS-CoV-2 main protease
por: Yang, Kai S., et al.
Publicado: (2022)

Mechanistic investigation of SARS-CoV-2 main protease to accelerate design of covalent inhibitors
por: Kim, Hoshin, et al.
Publicado: (2022)

Contribution of the catalytic dyad of SARS-CoV-2 main protease to binding covalent and noncovalent inhibitors
por: Kovalevsky, Andrey, et al.
Publicado: (2023)

Boroleucine‐Derived Covalent Inhibitors of the ZIKV Protease
por: Braun, Niklas J., et al.
Publicado: (2022)

Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188
por: Lockbaum, Gordon J., et al.
Publicado: (2021)

Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease
por: Macchiagodena, Marina, et al.
Publicado: (2022)

Supercomputer simulation of the covalent inhibition of the main protease of SARS-CoV-2
por: Nemukhin, A. V., et al.
Publicado: (2022)

The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors
por: Silvestrini, Lucia, et al.
Publicado: (2021)

High predictive QSAR models for predicting the SARS coronavirus main protease inhibition activity of ketone-based covalent inhibitors
por: Sepehri, Bakhtyar, et al.
Publicado: (2021)

Discovery of SARS-CoV-2 main protease covalent inhibitors from a DNA-encoded library selection
por: Ge, Rui, et al.
Publicado: (2022)

Selective covalent targeting of SARS-CoV-2 main protease by enantiopure chlorofluoroacetamide
por: Yamane, Daiki, et al.
Publicado: (2022)

Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine
por: Brewitz, Lennart, et al.
Publicado: (2023)

DNA-encoded chemical libraries yield non-covalent and non-peptidic SARS-CoV-2 main protease inhibitors
por: Jimmidi, Ravikumar, et al.
Publicado: (2023)

Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease
por: Ngo, Chau, et al.
Publicado: (2023)

Identification of covalent active site inhibitors of dengue virus protease
por: Koh-Stenta, Xiaoying, et al.
Publicado: (2015)

Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors
por: Zain, Rula, et al.
Publicado: (2021)

Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors
por: Amin, Sk. Abdul, et al.
Publicado: (2021)

Food phytochemicals, epigallocatechin gallate and myricetin, covalently bind to the active site of the coronavirus main protease in vitro
por: Kato, Yoji, et al.
Publicado: (2021)

Virtual screening for small molecular non-covalent binders of the SARS-CoV-2 main protease
por: Lipiński, Piotr F.J., et al.
Publicado: (2021)

In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking
por: Vázquez-Mendoza, Luis Heriberto, et al.
Publicado: (2022)

Synthesis of the Novel Covalent Cysteine Proteases Inhibitor with Iodoacetic Functional Group
por: Hartman, Kinga, et al.
Publicado: (2020)

The Se–S Bond Formation in the Covalent Inhibition Mechanism of SARS-CoV-2 Main Protease by Ebselen-like Inhibitors: A Computational Study
por: Parise, Angela, et al.
Publicado: (2021)

An integrated metabolomic and proteomic approach for the identification of covalent inhibitors of the main protease (M(pro)) of SARS-COV-2 from crude natural extracts
por: Baron, Giovanna, et al.
Publicado: (2023)

Identification of non-covalent SARS-CoV-2 main protease inhibitors by a virtual screen of commercially available drug-like compounds
por: Zhang, Linlin, et al.
Publicado: (2021)

Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease
por: Delre, Pietro, et al.
Publicado: (2020)

Individual and common inhibitors of coronavirus and picornavirus main proteases
por: Kuo, Chih-Jung, et al.
Publicado: (2009)

Ensemble Docking Coupled to Linear Interaction Energy Calculations for Identification of Coronavirus Main Protease (3CL(pro)) Non-Covalent Small-Molecule Inhibitors
por: Jukič, Marko, et al.
Publicado: (2020)

Novel covalent and non-covalent complex-based pharmacophore models of SARS-CoV-2 main protease (M(pro)) elucidated by microsecond MD simulations
por: Hayek-Orduz, Yasser, et al.
Publicado: (2022)

A Fragment-Based Method to Discover Irreversible Covalent Inhibitors of Cysteine Proteases
por: Kathman, Stefan G., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_eank9b3tvcnr72nnjlfb81kg8h